SNSantosh Nagaraju

Santosh Nagaraju

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Santosh Nagaraju has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Improved LCP Tacrolimus Dosing and Monitoring Outcomes With a Genotype‐Based Dosing Algorithm Versus Weight Based Dosing

    by Christine S. Wolesensky, Neha Patel, Santosh Nagaraju, Steve Hanish, Morgan Roberts, Margaret Dorsett, David J. Taber

    The aim of this study was to assess the impact of CYP3A5 genotype‐based LCP tacrolimus (tac) versus weight‐based dosing among adult kidney transplant recipients. This was a retrospective longitudinal matched cohort analysis. From February 2021 to June 2023, LCP tac was dosed using standard weight‐based dosing. Starting in June 2023, genotype‐based dosing was used; 148 patients were included (74 in each arm). Baseline characteristics were well balanced between the groups, except for age (control 46 ± 14 vs. 52 ± 14 years, p < 0.01); 32% were females, 36% were African American, 84% were living donors, 40% had DM, and 10% had DGF. At 90‐days post‐txp, the genotype guided cohort had an average of two fewer tacrolimus dose adjustments per patients (4 vs. 6, p < 0.0001), spent longer time in therapeutic range (59% vs. 47%, p = 0.004), and less time in concerning range (9% vs. 18%, p < 0.0001). Acute rejection, de novo donor specific antibodies, and eGFR was similar between the two cohorts. This matched cohort analysis assessing a genotype‐based dosing algorithm demonstrated improved LCP tac dosing efficiency. Patients on average, needed two fewer dose adjustments, spent longer time in therapeutic range and had significantly less time in concerning range.


  • Open Access

    Results of a Randomized Controlled Trial Evaluating the Impact of Conversion to LCP Tacrolimus on Neurologic Toxicities in Liver Transplant Recipients

    by Kelsey S. Coffman, Gonzalo J. Revuelta, Nathan DeTurk, Charles Palmer, Hannah Culpepper, Morgan Overstreet, James Fleming, Kathleen Terry, Neha Patel, John McGillicuddy, et al.

    Background/Aims: Neurotoxicity is commonly seen in liver transplant (LT) patients receiving tacrolimus. We sought to determine the impact of LCP tacrolimus on neurologic toxicity in LT recipients. Methods: This single‐center, semiblinded, parallel group randomized controlled trial compared neurotoxicity burden in LT patients receiving immediate‐release (IR) tacrolimus versus LCP tacrolimus. Thirty LT recipients transplanted between January 2020 and February 2022 were enrolled between 15 and 364 days posttransplant and followed for 6 months postrandomization. The primary endpoint was change from baseline to 6 months in composite Patient Global Impression of Improvement (PGI‐I) score. Select secondary endpoints included change in Fahn–Tolosa–Marin (FTM) Tremor Rating Scale, IMAB‐Q10, SF‐12, and Medical Symptom Validity Test (MSVT) scores. Results: No significant differences were seen in composite PGI scores, though all patients saw improvement in overall PGI scores (IR −5 [−13.5 to −0.25] vs. LCP −4 [−9.5 to −0.5], p = 0.78). Other tests examining neurotoxicities showed no difference between groups but an overall trend toward improvement in symptoms between baseline and end of study. One episode of moderate rejection (rejection activity index [RAI] score of 6) was reported in the LCP group, with no episodes in the IR group ( p = 0.31). No graft loss or mortality occurred in either group. Conclusions: Our study showed LCP tacrolimus had similar rates of neurotoxicity in LT recipients compared to IR without increasing the risk of rejection, graft loss, or mortality; these results suggest LCP tacrolimus can be a safe alternative in LT recipients. Trial Registration: ClinicalTrials.gov identifier: NCT03823768


  • Open Access

    REVIEW OF THE INTRODUCTION OF WHOLE GENOME SEQUENCING AS NHS STANDARD OF CARE FOR BRAIN TUMOUR PATIENTS AT QUEEN ELIZABETH HOSPITAL BIRMINGHAM, UK

    by Victoria Wykes, Meena Hyatt, Aimee Goel, Shefali Parikh, Fred Berki, Naomi Cole, Sarah Freeth, William Garratt, Claire Goddard, Ute Pohl, et al.

    Describe delays in the NHS pathway from initial consent for whole genome sequencing (WGS) to delivery of the final WGS report (WGS-R) to the treating oncologist. Review number of patients with mutations that inform, diagnosis, prognosis or treatment. Prospective audit of time to key stages along WGS pathway and review of final WGS-R. WGS pathway and process: Data snapshot at 24/02/2023 showed 96 patients consented for WGS: 12/96 awaiting surgery; 41/96 awaiting GTAB discussion; 1/96 WGS sample used for histopathological diagnosis, 1/96 ineligible. 41/96 WGS results discussed at a GTAB meeting; 39/44 with complete WGS-R sent to the treating oncologist, including discussion at the local neuro-oncology multi-disciplinary team meeting. Median time from consent to final WGS-R was 225 days (range 145-567). WGS results: 4 patients with glioblastoma (GBM) have RB1 variant, associated with improved progression-free and overall survival (Dono et al 2021). 10 patients had clinically actionable mutations with recommended trials or compassionate-use drugs. 1/10 patient with GBM and High Tumour Mutational Burden who completed standard of care (SOC) treatment has commenced anti-PD1 immunotherapy (Nivolumab; Goodman et al 2017). 5/10 patients are currently on SOC treatment, 3/10 had deteriorated and 1/10 were deceased at time of WGS-R. Excellent concordance of WGS data with SOC genetic/immunohistochemistry testing. No germline mutations identified. Nearly a third of patients had genetic variants that may have the potential to inform future clinical management. Further investment in the WGS pathway is required to deliver timely results to allow application of precision medicine for brain cancer patients.

  • Open Access

    Successful transplantation of LUCAS device assisted uncontrolled DCD kidneys with prolonged relative warm ischemia time: An underutilized option in North America

    by Santosh Nagaraju, Rachel Savilla, Myla Moore, Alice Jones, Joseph Africa

    Approximately 25% of deceased donors in the United States are procured in a donation after circulatory death (DCD) setting. Successful transplant outcomes from uncontrolled DCD (uDCD) practices have been reported in multiple European programs. They utilize established protocols for uDCD procurement with normo‐thermic or hypothermic regional perfusion to reduce ischemic damage. Further, manual or mechanical chest compressions using extrinsic devices, such as the LUCAS device, are implemented to maintain circulation before organ retrieval. Currently, uDCDs are not a major part of DCD organ utilization in the United States. We report our experience with utilization of kidneys from uDCD with the use of the LUCAS device without normothermic or hypothermic regional perfusion. We transplanted four kidneys from three uDCD donors without utilization of in situ regional perfusion and with prolonged relative warm ischemia time (rWIT) (>100 min). All recipients had functional renal allografts and improved renal function after the transplant. To our knowledge, this is the 1st successful series reported in the United States of the utilization of kidneys from uDCDs without the utilization of in situ perfusion to maintain organ preservation with prolonged rWIT.

  • Open Access

    Recurrence of Hyperoxaluria and Kidney Disease after Combined Intestine-Kidney Transplantation for Enteric Hyperoxaluria

    by Burcin Ekser, Richard S. Mangus, Chandrashekhar A. Kubal, Jonathan A. Fridell, John A. Powelson, Santosh Nagaraju, Plamen Mihaylov, Carrie L. Phillips, Romil Saxena, William C. Goggins

    Background: Enteric hyperoxaluria (EH) occurs with a rate of 5-24% in patients with inflammatory bowel disease, ileal resection and modern bariatric surgery. The excessive absorption of calcium oxalate causes chronic kidney disease (CKD) in patients with EH. In the literature, a single experience was reported in combined intestine-kidney transplantation (CIKTx) in patients with CKD due to EH. Methods: After a report of 2 successful cases of CIKTx in patients with EH and CKD, one was performed at our center in a 59-year-old Caucasian female who developed intestinal failure with total parenteral nutrition (TPN) dependence after a complication post-bariatric surgery. Before CIKTx, she underwent kidney transplantation alone (KTA) twice, which failed due to oxalate nephropathy. Results: In July 2014, the patient underwent CIKTx and bilateral allograft nephrectomy to avoid EH and oxalate stone burden. The postoperative course was complicated with acute tubular necrosis due to the use of high pressors related to perioperative bleeding. The patient was discharged 79 days after CIKTx with a serum creatinine (sCr) of 1.2 mg/dl and free of TPN. Her sCr increased at 7 months and a renal biopsy showed oxalate nephropathy. SLC26A6 (oxalate transporter) staining was significantly diminished in native duodenum/rectum as well as in intestinal allograft compared to control. Conclusions: KTA in patients with CKD secondary to EH should not be recommended due to high risk of recurrence. Although other centers showed good long-term outcomes in CIKTx, our patient experienced recurrence of EH due to oxalate transporter defect, early kidney allograft dysfunction and prolonged antibiotic use.